- (HETERO) ARYL IMIDAZOLONE COMPOUND
-
PROBLEM TO BE SOLVED: To provide a novel compound that has an inhibitory action on prolyl hydroxylases (PHDs), and is useful as a treatment agent for inflammatory bowel diseases such as ulcerative colitis. SOLUTION: The present disclosure provides a (hetero) aryl imidazolone compound represented by the formula (I) or a pharmacologically acceptable salt thereof (where m, u, p, q and r each denote a specific integer, E, G, Q and T each denote a specific group such as N or CH, W and Z each denote a specific ring, R1 and R3 each denote a specific group such as a halogen atom). SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT
- -
-
Paragraph 0087; 0090
(2021/08/13)
-
- 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30.
-
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R1, R 2, R 3, m, L and X are as defined herein.
- -
-
-
- New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation
-
We report the development of the novel N-substituted benzimidazole 11 as a potent and selective human formyl peptide receptor-like 1 (hFPRL1) agonist. This compound and its less active enantiomer 12 were identified as useful tools for studying receptor function in vitro.
- Frohn, Mike,Xu, Han,Zou, Xiaoming,Chang, Catherine,McElvaine, Michele,Plant, Matthew H.,Wong, Min,Tagari, Philip,Hungate, Randall,Buerli, Roland W.
-
p. 6633 - 6637
(2008/03/18)
-